Murray G J, Jin F S
Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
J Histochem Cytochem. 1995 Feb;43(2):149-58. doi: 10.1177/43.2.7822772.
Knowledge of the cellular distribution and subcellular localization of mannose-terminal glucocerebrosidase after intravenous infusion is necessary for understanding the efficacy of targeted enzyme replacement therapy for Gaucher's disease. Selective uptake of mannose-terminal glucocerebrosidase by Kupffer cells in rat liver has been previously demonstrated biochemically. In this study we used immunohistochemical and immunogold labeling techniques to provide direct visual proof for the localization of the delivered enzyme. Light microscopy confirmed biochemical data identifying non-parenchymal cells as the primary target of the modified glucocerebrosidase. Using a primary antibody specific for glucocerebrosidase and a secondary gold-conjugated antibody, we used immunoelectron microscopy to quantify the extent and distribution of exogenous enzyme in various cell types in rat liver and its localization within their respective subcellular organelles. Thirty minutes after intravenous administration of mannose-terminal glucocerebrosidase, enzyme was localized primarily in lysosomes of Kupffer cells. Of eight intact Kupffer cells counted, 16 of 21 lysosomes (78%) contained immunogold conjugates (average concentration 293 gold particles/micron 2). Of 589 particles counted in these lysosomes, 485 (82%) were localized within the lumen of the lysosome; only 104 (18%) were membrane-associated. Five of the 21 lysosomes counted were negative for gold. No gold particles were found in the mitochondria of Kupffer cells and very few particles (8.2/microns 2) were found over the nucleus. The density of gold particles was also low over the nucleus (7.2/microns 2), mitochondria (8.8/microns 2), and lysosomes (7.9/microns 2) of hepatocytes. No specific labeling was observed in erythrocytes, platelets, lymphocytes, pit cells, fat-storing cells, or bile duct. Background labeling of control liver sections from rats receiving saline injection was 8.2 +/- 1.4 gold particles/microns 2. We conclude that mannose-terminal glucocerebrosidase is delivered to the lysosomes of Kupffer cells in liver and that it is distributed both within the lumen (82%) and over the membrane (18%) of the lysosome, with a slight preferential association with the membrane. These findings may provide insights into the design of more effective therapeutic enzyme preparations for the treatment of Gaucher's disease.
了解静脉输注后甘露糖末端葡萄糖脑苷脂酶的细胞分布和亚细胞定位对于理解戈谢病靶向酶替代疗法的疗效至关重要。先前已通过生化方法证明大鼠肝脏中的库普弗细胞可选择性摄取甘露糖末端葡萄糖脑苷脂酶。在本研究中,我们使用免疫组织化学和免疫金标记技术为递送的酶的定位提供直接的视觉证据。光学显微镜证实了生化数据,确定非实质细胞是修饰的葡萄糖脑苷脂酶的主要靶标。使用对葡萄糖脑苷脂酶特异的一抗和二抗金缀合物,我们用免疫电子显微镜定量了大鼠肝脏中各种细胞类型中外源酶的程度和分布及其在各自亚细胞器内的定位。静脉注射甘露糖末端葡萄糖脑苷脂酶30分钟后,酶主要定位于库普弗细胞的溶酶体中。在计数的8个完整库普弗细胞中,21个溶酶体中的16个(78%)含有免疫金缀合物(平均浓度293个金颗粒/微米2)。在这些溶酶体中计数的589个颗粒中,485个(82%)定位于溶酶体腔内;只有104个(18%)与膜相关。计数的21个溶酶体中有5个金染色阴性。在库普弗细胞的线粒体中未发现金颗粒,在细胞核上发现的颗粒很少(8.2/微米2)。肝细胞的细胞核(7.2/微米2)、线粒体(8.8/微米2)和溶酶体(7.9/微米2)上的金颗粒密度也很低。在红细胞、血小板、淋巴细胞、pit细胞、贮脂细胞或胆管中未观察到特异性标记。接受盐水注射的大鼠的对照肝脏切片的背景标记为8.2±1.4个金颗粒/微米2。我们得出结论,甘露糖末端葡萄糖脑苷脂酶被递送至肝脏中库普弗细胞的溶酶体,并且它分布于溶酶体腔(82%)和膜(18%)上,与膜有轻微的优先结合。这些发现可能为设计更有效的治疗戈谢病的治疗性酶制剂提供见解。